Article

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays

2017-04-07

Abstract excerpt

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are mutated in a variety of cancers to confer a gain-of-function activity resulting in the accumulation and secretion of an oncometabolite, D-2-hydroxyglutarate (2-HG). Accumulation of 2-HG can result in epigenetic dysregulation and a block in cellular differentiation, suggesting these mutations play a role in neoplasia. Based on its p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c13d848e-5c6e-5bde-a51e-3a20b463bcef
DOI: 10.1101/124024

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysDOI 10.1101/124024Read

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.Semantic proximity Read

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.Semantic proximity Read

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma CellsSemantic proximity Read

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.Semantic proximity Read

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersSemantic proximity Read

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read

Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.Semantic proximity Read